Obrixtamig plus standard therapy for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a new drug, obrixtamig, to the usual first treatment for extensive-stage small cell lung cancer can help people live longer or slow the cancer's growth. The usual treatment is a combination of atezolizumab, carboplatin, and etoposide.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage small cell lung cancer.
- You have not had previous treatment for this stage of lung cancer.
- A small sample of your tumor tissue must be available for testing.
- You are generally able to care for yourself (performance status 0 or 1).
- You have not had prior treatment that targets the DLL3 protein.
- You do not have active autoimmune disease requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This study tests a new combination of two investigational drugs, obrixtamig and ZL-1310, for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This trial tests two new immunotherapy drugs (obrixtamig and pumitamig) given together for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and helps shrink or control the cancer.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.